Polymer-free drug-coated coronary stents in patients at high bleeding risk

New England Journal of Medicine

Volumn 373, Issue 21, 2015, Pages 2038-2047

  Urban, Philip ^a   Meredith, Ian T ^d   Abizaid, Alexandre ^e   Pocock, Stuart J ^f   Carrié, Didier ⁱ   Naber, Christoph ^p   Lipiecki, Janusz ^j   Richardt, Gert ^q   Iñiguez, Andres ^r   Brunel, Philippe ^k   Valdes Chavarri, Mariano ^s   Garot, Philippe ^l   Talwar, Suneel ^g   Berland, Jacques ^m   Abdellaoui, Mohamed ⁿ   Eberli, Franz ^b   Oldroyd, Keith ^h   Zambahari, Robaayah ^t   Gregson, John ^f   Greene, Samantha ^c   Stoll, Hans Peter ^c   Morice, Marie Claude ^o   more..

^a LA TOUR HOSPITAL   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

^c Biosensors International   (Switzerland)

^d MONASH UNIVERSITY   (Australia)

^e INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^h GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

ⁱ CHU RANGUEIL   (France)

^j Pole Santé République Centre de Cardiologie Interventionelle   (France)

^k Clinique de Fontaine   (France)

^l INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

^m Clinique Saint Hilaire   (France)

ⁿ Groupe Hospitalier Mutualiste de Grenoble   (France)

^o INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

^p ELISABETH KRANKENHAUS ESSEN   (Germany)

^q Herzzentrum Segeberger Kliniken   (Germany)

^r HOSPITAL DO MEIXOEIRO   (Spain)

^s HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^t NATIONAL HEART INSTITUTE   (Malaysia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; IMMUNOSUPPRESSIVE AGENT; POLYMER; RAPAMYCIN; UMIROLIMUS;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; BIOLIMUS ELUTING CORONARY STENT; BLEEDING; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENTING; DEVICE SAFETY; DOUBLE BLIND PROCEDURE; FEMALE; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; TREATMENT OUTCOME; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ELUTING STENT; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS; STENT;

AGED; COMBINED MODALITY THERAPY; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; POLYMERS; PROSTHESIS DESIGN; SIROLIMUS; STENTS;

EID: 84947753606     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1503943     Document Type: Article

References (23)

1. Morice M-C, Urban P, Greene S, Schuler G, Chevalier B. Why are we still using coronary bare-metal stents? J Am Coll Cardiol 2013;61:1122-3.
2. Urban P, Abizaid A, Chevalier B, et al. Rationale and design of the LEADERS FREE trial: a randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplate-let therapy. Am Heart J 2013; 165: 704-9.
3. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocar-dial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Tho-racic Surgery (EACTS). Eur Heart J 2014; 35:2541-619.
4. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124:2574-609.
5. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-206.
6. Tada N, Virmani R, Grant G, et al. Polymer-free Biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting Cypher stent in a porcine model. Circ Cardiovasc Interv 2010;3:174-83.
7. Costa RA, Abizaid A, Mehran R, et al. Polymer-free biolimus A9-coated stents in the treatment of de novo coronary lesions: 4-and 12-month angiographic follow-up and final 5-year clinical outcomes of the prospective, multicenter BioFreedom FIM clinical trial. J Am Coll Cardiol Intv (in press).
8. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 2009; 119: 1873-82.
9. Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107-15.
10. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012;126:2020-35.
11. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
12. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123:2736-47.
13. Gwon H-C, Hahn J-Y, Park KW, et al. Six-month versus 12-month dual anti-platelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Pro-mus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012; 125: 505-13.
14. Collet J-P, Silvain J, Barthélémy O, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 2014;384:1577-85.
15. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155-66.
16. Berger PB, Bhatt DL, Fuster V, et al. Bleeding complications with dual anti-platelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopi-dogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 2010;121:2575-83.
17. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
18. Lopes RD, Alexander KP, Manoukian SV, et al. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheter-ization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009; 53: 1021-30.
19. Pilgrim T, Heg D, Roffi M, et al. Ultrathin strut biodegradable polymer siro-limus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet 2014;384:2111-22.
20. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008;372:1163-73.
21. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:136-46.
22. Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol 2015; 65: 805-15.
23. Urban P, Abizaid A, Banning A, et al. Stent thrombosis and bleeding complications after implantation of sirolimus-elut-ing coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry. J Am Coll Cardiol 2011;57:1445-54.